Ongoing studies - general overview
- Effect of nutritional intervention on growth, metabolism, inflammation, and cardiovascular
disease in preterm infants - Steroid profiles from birth to 36 weeks PMA in very preterm newborns
- Myocardial function in sick newborns and further method development
- Cardiac function and circulatory status in term and preterm infants with intrauterine
growth restriction - Further development of EEG studies in preterm infants
- Group B streptococci in women giving birth and newborns; a clinical, epidemiological, and
microbiological study - Born in the twilight of antibiotics: Development of the microbiome and resistome in preterm infants
- The ALBINO study
- The ImNuT study
- Non-invasive monitoring of preterm infants using surveillance data and electronic noses (Phase 1 of BePREPArED)
- Nicotine as a neuroprotective agent in perinatal asphyxia
Quality improvement projects:
- Infection prevention measures for very preterm infants, temperature project, rapid antibiotic administration,
kangaroo care at admission, timing of umbilical cord clamping
Major research projects
- The ImNuT study; effect of nutritional intervention on growth, metabolism, inflammation, and
cardiovascular disease in preterm infants. (A double-blind, randomized clinical trial).
This study involves translational research and is divided into three work packages. Enrollment
concluded in January 2021. Planned follow-up extends to 8 years of age, i.e., until May 2029. - BePREPArED; Innovation study that has received seed funding from the Novo Nordisk Foundation and VekstHuset (OUS). This study is also part of the SPARK program at the University of Oslo (UiO).
National/international multicenter studies
- The ALBINO study: Allopurinol prophylaxis for birth asphyxia. An international clinical multicenter study with participants from several European countries; EU-funded, coordinated from Germany. Concluded in 2024. The final patient’s 2-year follow-up is scheduled for spring 2026.